# US 2019/0376035 A1 · Granulocytic myeloid-derived suppressor cells (GR-MDSC) accumulate in human breastmilk

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0376035 A1
- Document ID: US20190376035A1
- Status: Published application
- Kind: A1
- Application number: 16/431,421
- Filed: 2019-06-04
- Published: 2019-12-12
- Earliest claimed: 2018-06-06
- Assignees: Eberhard Karls Universitaet Tuebingen Medizinische Fakultaet
- Applicants: Eberhard Karls Universitaet Tuebingen Medizinische Fakultaet
- Inventors: Natascha Koestlin; Christian Gille
- Web page: https://patentgrep.com/patent/US20190376035A1

## CPC

- C12N 5/0642: {Granulocytes, e.g. basopils, eosinophils, neutrophils, mast cells}
- A61K 40/10: characterised by the cell type used
- A61K 40/22: Immunosuppressive or immunotolerising
- A61K 40/416: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance}
- C07K 16/2803: {against the immunoglobulin superfamily}
- C12N 5/0634: {Cells from the blood or the immune system}
- A61K 35/20: Milk; Whey; Colostrum
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention relates to myeloid-derived suppressor cells (MDSC) and exosomes derived therefrom (MDSC exo) and application thereof.

## Claims

### Claim 1

A method of preparing myeloid-derived suppressor cells (MDSC) comprising a step of isolating MDSC from breast milk.

### Claim 2 (depends on 2)

The method of claim 2, wherein the step of isolating MDSC from breast milk includes the following sub-steps:
providing breast milk obtained from a breastfeeding female individual,
centrifuging the breast milk to pelletize the milk cells,
discarding the supernatant and washing the pelletized milk cells to obtain the MDSC.

### Claim 3 (depends on 2)

The method of claim 2, wherein the pelletized milk cells are incubated with an anti-MDSC antibody, followed by a separation of MDSC complexed with the anti-MDSC antibody, followed by a disengagement of the MDSC from the anti-MDSC antibody, thereby obtaining the MDSC.

### Claim 4 (depends on 3)

The method of claim 3, wherein the anti-MDSC antibody is an anti-CD66b antibody.

### Claim 5 (depends on 1)

The method of claim 1, wherein the MDSC comprise granulocytic myeloid-derived suppressor cells (GR-MDSC).

### Claim 6 (depends on 1)

The method of claim 1, wherein the obtained MDSC are subjected to a density gradient centrifugation to separate granulocytic myeloid-derived suppressor cells (GR-MDSC) from monocytic myeloid-derived suppressor cells (MO-MDSC).

### Claim 7

A method of preparing myeloid-derived suppressor cells (MDSC) derived exosomes (MDSC exo) comprising a step of isolating MDSC exo from breast milk.

### Claim 8 (depends on 7)

The method of claim 7 comprising the following steps:
providing isolated MDSC from breast milk,
cultivating said isolated MDSC in cell culture medium,
centrifuging said MDSC containing cell culture medium to obtain a supernatant and a pellet, and
isolating MDSC exo from the supernatant.

### Claim 9 (depends on 8)

The method of claim 8, wherein the isolation of MDSC exo from the supernatant includes one or more of the following procedures: centrifugation, ultracentrifugation, filtration, membrane filtration, microporous membrane filtration.

### Claim 10 (depends on 8)

The method of claim 8, wherein the MDSC exo comprise granulocytic myeloid-derived suppressor cells derived exosomes (GR-MDSC exo).

### Claim 11

A method of treatment of a living being, comprising the administration of myeloid-derived suppressor cells (MDSC) or MDSC derived exosomes (MDSC exo) isolated from breast milk.

### Claim 12 (depends on 11)

The method of claim 11, wherein the MDSC comprise granulocytic myeloid-derived suppressor cells (GR-MDSC) and the MDSC exo comprise granulocytic myeloid-derived suppressor cells derived exosomes (GR-MDSC exo).

### Claim 13 (depends on 11)

The method of claim 11, wherein said treatment is a treatment of a pathological condition selected from the group consisting of: bacterial infection, nosocomial bacterial infection (NBI), immune system disorder, inflammation, neonatal inflammation, enterocolitis, necrotizing enterocolitis (NEC), autoimmune disease.

### Claim 14 (depends on 13)

The method of claim 13, wherein said living being is selected from the group consisting of: human new-born, human very low birth weight infant (VLBW).

### Claim at position 15

15-20. (canceled)
